Harrow acquires NDA for Triesence
Click Here to Manage Email Alerts
Harrow announced an early completed transfer of the new drug application for Triesence, a synthetic corticosteroid for treatment of several inflammatory ophthalmic conditions, including those not responsive to topical corticosteroids.
According to a company press release, Harrow agreed to acquire the U.S. commercial rights to Triesence 40 mg/mL (triamcinolone acetonide injectable suspension) in January 2023. While the transfer was completed ahead of the previously determined date, other terms of the acquisition remain the same.
“While we continue to diligently work with our contract manufacturing partner, making solid progress manufacturing commercial batches of Triesence, the mutual agreement to an early transfer of the Triesence NDA was an important step in advancing our strategy to relaunch the product under the Harrow umbrella,” Mark L. Baum, CEO of Harrow, said in the release.
Triesence, which was acquired by Harrow with four other ophthalmic products, is designed to treat sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions that do not respond to topical corticosteroids. The product is also indicated for visualization during vitrectomy, the release stated.
“With this crucial process completed, our team has begun to implement our market access, marketing, inventory management, national sales detailing and other brand-leveraging strategies so that we will be ready to relaunch Triesence in the U.S. once we have achieved a successful inventory build, which we are currently working diligently towards,” Baum said in the release. “We remain excited to be able to provide Triesence to the U.S. ophthalmic community soon.”
Read more about
Click Here to Manage Email Alerts